无水氯化钙

无水氯化钙用途

用途一：用作冷冻剂，也用于食品加工、制药等
用途二：在食品工业中用作钙质强化剂、螯合剂、固化剂和冷冻用致冷剂。
用途三：作饲料钙补充。
用途四：作凝固剂，我国规定可在豆制品中按生产需要适量使用。
用途五：用作冷冻剂(如冷冻机用冷冻盐水、制冰和制冰棒时用冷冻盐水)、防冻剂、汽车防冻液、灭火剂。用于熔冰和熔雪，棉织物的整理和精加工的阻燃剂。用作胶黏剂和木材防腐剂。是制造无水氯化钙的原料。用于墙壁粉刷及抹灰作业中，增加凝结能力。橡胶生产用作凝析剂。混合淀粉糊用作上胶剂。还用于有色金属冶炼。用作医药品。
用途六：氧、硫吸收剂。食物保护剂。上浆剂。净水剂。防冻剂。

无水氯化钙名称

[ CAS 号 ]:
10043-52-4

[ 中文名 ]:
无水氯化钙

[ 英文名 ]:
Calcium chloride

[中文别名 ]:

[英文别名 ]:

Jarcal
Calplus
Peladow
Dowflake
EINECS 233-140-8
Calcium chloride
Caloride
MFCD00010903
Caltac
CaCl2

无水氯化钙物理化学性质

[ 密度 ]:
1.086 g/mL at 20 °C

[ 沸点 ]:
1600 °C

[ 熔点 ]:
772 °C(lit.)

[ 分子式 ]:
CaCl₂

[ 分子量 ]:
110.984

[ 闪点 ]:
>1600°C

[ 精确质量 ]:
109.900299

[ LogP ]:
1.37900

[ 外观性状 ]:
白色固体

[ 蒸汽压 ]:
0.01 mm Hg ( 20 °C)

[ 折射率 ]:
n20/D 1.358

[ 储存条件 ]:
库房低温通风干燥,防水,防潮

[ 稳定性 ]:
Stable. Incompatible with zinc, water, strong acids, methyl vinyl ether, bromine trifluoride, boron oxide, calcium oxide. Hygroscopic.

[ 水溶解性 ]:
740 g/L (20 ºC)

无水氯化钙MSDS

详细MSDS(安全技术说明书)

无水氯化钙毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: EV9800000

CHEMICAL NAME :: Calcium chloride

CAS REGISTRY NUMBER :: 10043-52-4

LAST UPDATED :: 199710

DATA ITEMS CITED :: 33

MOLECULAR FORMULA :: Ca-Cl2

MOLECULAR WEIGHT :: 110.98

WISWESSER LINE NOTATION :: CA G2

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 20 mg/kg/1H-C

TOXIC EFFECTS :: Skin and Appendages - dermatitis, other (after systemic exposure) Nutritional and Gross Metabolic - changes in calcium

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 264 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 2630 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 161 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 25 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1940 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 210 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold Behavioral - changes in motor activity (specific assay)

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 823 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 42 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 274 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 274 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Mammal - cat

DOSE/DURATION :: 249 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - cat

DOSE/DURATION :: 249 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 1384 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 472 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 274 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 150 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intraarterial

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 300 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Amphibian - frog

DOSE/DURATION :: 666 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 2016 mg/kg/30D-I

TOXIC EFFECTS :: Brain and Coverings - recordings from specific areas of CNS Cardiac - pulse rate Blood - changes in leukocyte (WBC) count

TYPE OF TEST :: TCLo - Lowest published toxic concentration

ROUTE OF EXPOSURE :: Inhalation

SPECIES OBSERVED :: Mammal - species unspecified

DOSE/DURATION :: 43 mg/m3/4H/17W-I

TOXIC EFFECTS :: Blood - change in clotting factors Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - catalases

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 112 gm/kg/20W-C

TOXIC EFFECTS :: Tumorigenic - equivocal tumorigenic agent by RTECS criteria Endocrine - thyroid tumors

TYPE OF TEST :: Unscheduled DNA synthesis

MUTATION DATA

TYPE OF TEST :: Cytogenetic analysis

TEST SYSTEM :: Rodent - rat Ascites tumor

DOSE/DURATION :: 3500 mg/kg

REFERENCE :: GANNA2 Gann. Japanese Journal of Cancer Research. (Tokyo, Japan) V.1-75, 1907-84. For publisher information, see JJCREP. Volume(issue)/page/year: 54,155,1963 *** U.S. STANDARDS AND REGULATIONS *** EPA FIFRA 1988 PESTICIDE SUBJECT TO REGISTRATION OR RE-REGISTRATION FEREAC Federal Register. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) V.1- 1936- Volume(issue)/page/year: 54,7740,1989 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 15720 No. of Facilities: 7996 (estimated) No. of Industries: 87 No. of Occupations: 79 No. of Employees: 110691 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 15720 No. of Facilities: 15168 (estimated) No. of Industries: 116 No. of Occupations: 113 No. of Employees: 354620 (estimated) No. of Female Employees: 117433 (estimated)

无水氯化钙安全信息

[ 符号 ]:

GHS07

[ 信号词 ]:
Warning

[ 危害声明 ]:
H319

[ 警示性声明 ]:
P305 + P351 + P338

[ 个人防护装备 ]:
Eyeshields;Faceshields;Gloves

[ 危害码 (欧洲) ]:
Xi:Irritant

[ 风险声明 (欧洲) ]:
R36

[ 安全声明 (欧洲) ]:
S26-S39-S24-S22-S36

[ 危险品运输编码 ]:
UN 1789 8/PG 3

[ WGK德国 ]:
1

[ RTECS号 ]:
EV9810000

[ 危险类别 ]:
8.0

[ 海关编码 ]:
2827200000

无水氯化钙制备

（一）食用无水氧化钙：
1.喷雾干燥脱水法：将已除去砷和重金属的精制中性氯化钙溶液，通过喷嘴从喷雾干燥塔上方喷成雾状，与300℃热气流进行逆流接触达到干燥脱水，得到粉末状无水氯化钙，制得食用无水氯化钙成品。
（二）工业无水氧化钙：
1..脱水法将二水氯化钙于200～300℃下进行干燥脱水，制得无水氯化钙成品，其反应方程式如下：

对于中性氯化钙溶液，可采用喷雾干燥塔，在300℃热气流下进行喷雾干燥脱水，制得无水氯化钙粉末状成品。
2.由氨碱法制纯碱时的母液，加石灰乳而得水溶液，经蒸发、浓缩、冷却、固化而成。
由碳酸钙与盐酸作用而得。生产次氯酸钠中的副产品经精制而成。 3.向600mL 12%的稀盐酸中加入100g碳酸钙，同时搅拌，即有CO2放出，并形成氯化钙溶液，滤去不溶性杂质，将滤液在水浴上加热浓缩，冷却至室温，即有六水合氯化钙析出，过滤，沉淀用滤纸吸干，将六水合物继续加热至200℃，脱水，然后在800℃熔融即成无水氯化钙。 4. 采用纯碱废液回收法。将纯碱生产的蒸馏废液连续蒸发，使其浓度增加到含CaCL ₂69%～70%，以达到熔融氯化钙产品的要求。将二水氯化钙于200～300℃下干燥脱水，即得无水氯化钙。对于中性氯化钙溶液，亦可采用喷雾干燥塔，在300℃热气流下喷雾干燥，即得无水粉末状成品。（三）制法将工业氯化钙溶于水中，制得35%～40%的水溶液。用少量相对密度为1.19的盐酸进行酸化。根据原料中SO ₄ ^2-离子的含量，加入适量的30%的氯化钡水溶液（不过量），搅拌均匀，澄清后检验SO ₄ ^2- 离子和 Ca ²⁺离子至合格。静置。待沉淀完全后，滤去沉淀，滤液用试剂盐酸中和至甲基红呈玫瑰色而甲基橙呈黄色，然后用水稀释至相对密度为1.226，得到50%的氯化钙溶液。六水合氯化钙的制取：在上述50%氯化钙溶液中加入活性炭（每400ml溶液加1g活性炭），在90～100℃下蒸发浓缩到相对密度为1.37，冷却结晶，即可。二水合氯化钙的制取：将上述六水合物加热至200℃脱水即得二水合物。二水合氯化钙的制取：将上述六水合物加热至200℃脱水即得二水合物。无水氯化钙的制取：将二水合物在200～300℃下干燥脱水制得。
（四）石灰石法　将石灰石（CaCO33%≥95%）破碎后，加入溶解槽，按盐酸∶石灰石为2.2∶1的配比加入31%的工业盐酸，在搅拌下发生如下反应：反应生成的气体送入内部填充石灰石的喷淋塔内，并喷淋氯化钙稀溶液，由塔底得浓度为300～350g/L的氯化钙溶液，与来自溶解槽的氯化钙溶液混合后，加入氯化钡，使其中的硫酸根生成硫酸钡沉淀除去；将溶液再加热至70～75℃，加入石灰乳，调节溶PH值至8.5～9，使其中的铁、铝、镁等杂质形成氢氧化物沉淀除去。经澄清、过滤、蒸发，得到含量为70%以上的氯化钙溶液，利用喷雾干燥塔在400～450℃热气流下进行喷雾干燥脱水，制得无水氯化钙粉末状成品。

无水氯化钙海关

[ 海关编码 ]: 2827200000

无水氯化钙文献

Aptamer-based polyvalent ligands for regulated cell attachment on the hydrogel surface.

Biomacromolecules 16(4) , 1382-9, (2015)

Natural biomolecules are often used to functionalize materials to achieve desired cell-material interactions. However, their applications can be limited owing to denaturation during the material funct...

Synergistic activity of tenofovir and nevirapine combinations released from polycaprolactone matrices for potential enhanced prevention of HIV infection through the vaginal route.

Eur. J. Pharm. Biopharm. 88(2) , 406-14, (2014)

Polycaprolactone (PCL) matrices were simultaneously loaded with the antiviral agents, tenofovir (TFV) and nevirapine (NVP), in combination to provide synergistic activity in the prevention of HIV tran...

Calcium-induced conformational changes of the regulatory domain of human mitochondrial aspartate/glutamate carriers.

Nat. Commun. 5 , 5491, (2014)

The transport activity of human mitochondrial aspartate/glutamate carriers is central to the malate-aspartate shuttle, urea cycle, gluconeogenesis and myelin synthesis. They have a unique three-domain...

更多文献